Philipp Mann
Fred Hutchinson Cancer Research Center
6 Papers
62 Citations
Philipp Mann is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: HIV vaccine & Medicine. The author has an hindex of 4, co-authored 6 publications. Previous affiliations of Philipp Mann include National Institute for Medical Research.
Chat about Author
Papers
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
Lindsey R. Baden,Daniel J. Stieh,Michal Sarnecki,Stephen R. Walsh,Georgia D. Tomaras,James G. Kublin,M. Juliana McElrath,Galit Alter,Guido Ferrari,David C. Montefiori,Philipp Mann,Steven Nijs,Katleen Callewaert,Paul A. Goepfert,Srilatha Edupuganti,Etienne Karita,Johannes P. M. Langedijk,Frank Wegmann,Lawrence Corey,Maria G. Pau,Dan H. Barouch,Dan H. Barouch,Hanneke Schuitemaker,Frank Tomaka,Julie A Ake,Susan Buchbinder,Karen Buleza,Kristen W. Cohen,Trevor A Crowell,Zelda Euler,Ian Frank,Dimitri Goedhart,Michael C. Keefer,Colleen Kelly,Kenneth H. Mayer,Joseph P. Nkolola,Lauren Peter,Merlin L. Robb,Nadine Rouphael,Lorenz Scheppler,Magda Sobieszczyk,Hong Van Tieu +41 more
TL;DR: This study compared the safety, tolerability, and immunogenicity of a newly developed, tetravalent Ad26 vaccine with the previously tested trivalent formulation, which was found to elicit higher immune responses than the MITvalent regimen.
85
Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.
Patricia Munseri,Arne Kroidl,Charlotta Nilsson,Agricola Joachim,Christof Geldmacher,Philipp Mann,Candida Moshiro,Said Aboud,Eligius Lyamuya,Leonard Maboko,Marco Missanga,Bahati Kaluwa,Sayoki Mfinanga,Lilly Podola,Asli Bauer,Karina Godoy-Ramirez,Mary A. Marovich,Bernard Moss,Michael Hoelscher,Frances Gotch,Wolfgang Stöhr,Richard Stout,Sheena McCormack,Britta Wahren,Fred Mhalu,Merlin L. Robb,G. Biberfeld,Eric Sandström,Muhammad Bakari +28 more
TL;DR: A simplified intradermal vaccination regimen with 2 injections of a total of 600 μg with combined HIV-DNA plasmids primed cellular responses as efficiently as the standard regimen of 5 injections ofA total of 1000 μg with separated plasmid pools after boosting twice with HIV-MVA.
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
Mina C. Hosseinipour,Craig Innes,Sarita Naidoo,Philipp Mann,Julia Hutter,Gita Ramjee,Sebe M,Lucas Maganga,Michael E Herce,Allan C. deCamp,Kyle E. Marshall,One Dintwe,Erica Andersen-Nissen,Georgia D. Tomaras,Nonhlanhla N. Mkhize,Lynn Morris,Ryan L. Jensen,Miner,Giuseppe Pantaleo,S. Ding,Van Der Meeren O,Susan W. Barnett,MJ McElrath,Lawrence Corey,James G. Kublin +24 more
TL;DR: Both the prime/boost and coadministration regimens are safe and may be promising for advancement into efficacy trials depending on whether cellular or humoral responses are desired.
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.
Agricola Joachim,Asli Bauer,Sarah Joseph,Christof Geldmacher,Patricia Munseri,Said Aboud,Marco Missanga,Philipp Mann,Britta Wahren,Guido Ferrari,Victoria R. Polonis,Merlin L. Robb,Merlin L. Robb,Jonathan Weber,Roger Tatoud,Leonard Maboko,Michael Hoelscher,Michael Hoelscher,Eligius Lyamuya,Gunnel Biberfeld,Eric Sandström,Arne Kroidl,Arne Kroidl,Muhammad Bakari,Charlotta Nilsson,Charlotta Nilsson,Sheena McCormack +26 more
TL;DR: In this paper, the safety and impact of boosting with subtype C CN54rgp140 envelope protein adjuvanted in glucopyranosyl lipid adjuvant (GLA-AF) in Tanzanian volunteers previously given three immunizations with HIV-DNA followed by two immunisations with recombinant modified vaccinia virus Ankara (HIV-MVA).
Antibody and Cellular Responses to HIV Vaccine Regimens With DNA Plasmid as Compared With ALVAC Priming: An Analysis of Two Randomized Controlled Trials
Zoe Moodie,Stephen R. Walsh,Stephen R. Walsh,Stephen R. Walsh,Fatima Laher,Lucas Maganga,Michael E Herce,Sarita Naidoo,Mina C. Hosseinipour,Craig Innes,Linda-Gail Bekker,Nicole Grunenberg,Philipp Mann,Chenchen Yu,Allan C. deCamp,Maurine D. Miner,Nicole L. Yates,Jack Heptinstall,Nonhlanhla N. Mkhize,One Dintwe,Nicole Frahm,Kristen W. Cohen,Mary Allen,Julia Hutter,Ralf Wagner,Giuseppe Pantaleo,M. Juliana McElrath,Georgia D. Tomaras,Lynn Morris,David C. Montefiori,Erica Andersen-Nissen,Glenda Gray,Peter B. Gilbert,James G. Kublin,Hvtn trial teams +34 more
TL;DR: Analysis of DNA plasmid versus canarypox virus (ALVAC) primes in 2 randomized, double-blind, placebo-controlled trials in southern Africa with harmonized trial designs found binding antibody (bAb) responses to HIV antigens were >98% in both trials, with rates significantly higher for the DNA- Primed regimen than the ALVAC-primed regimen.